Expedeon AG announced that it has signed a supply and license agreement with Cell Guidance Systems for use of Expedeon's proprietary Lightning-Link(R) Rapid Biotin technology in the development and production of TRIFic(TM) (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays. Cell Guidance Systems has already benefitted from the application of Expedeon's Lightning-Link(R) technology for over two years, and under this new agreement Expedeon becomes preferred immunoreagent supplier to the company. Cell Guidance Systems' TRIFic(TM) rapid detection assay provides quantitative data from purified and unpurified samples, including direct measurements of exosomes in plasma. TRIFic(TM) exosome assays are available for widely used markers of exosomes, including the tetraspanin proteins CD9, CD63 and CD81, and provides high sensitivity detection levels which are clear and consistent over a wide range of samples. The Expedeon Lightning-Link(R) Rapid Biotin kit enables the rapid, direct biotinylation of antibodies, proteins and peptides, or any other biomolecule with an available amine group, with 100% recovery of materials. The kit is optimized for assays in which the biotinylated protein is captured by streptavidin immobilized on a surface. The kit requires only 30 seconds hands-on time and the conjugates are ready to use in under 20 minutes. The technology is fully scalable from 10ug to 1g or over, and is stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility. Using Expedeon's Lightning-Link(R) biotin technology will enable Cell Guidance Systems to manufacture TRIFic(TM) detection assays on-demand with highly reproducible and scalable results. Cell Guidance Systems will benefit from cost savings on detection antibodies and secondary immunoreagents, plus improved production yields and enhanced quality of immunoassay handling.